Group 1 - electroCore, Inc. announced the appointment of Seth Abrams as VP of Sales effective April 1, 2026, and Michael Fox as Chief Operating Officer effective April 13, 2026 [1] - The Compensation Committee granted 30,000 restricted stock units (RSUs) to Mr. Abrams and 70,000 RSUs to Mr. Fox as part of their employment inducement [1] - The RSUs will vest in three equal parts on the first, second, and third anniversaries of the grant date, contingent on continued employment [1] Group 2 - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore for chronic pain treatment and Quell® for fibromyalgia, utilizing non-invasive neuromodulation technology [2] - electroCore also markets handheld products like Trvuaga and TAC-STIM for general wellness and human performance enhancement [2]

A Bioelectronic Medicine & Wellness Company Nasdaq: ECOR Corporate Presentation March 2026 Forward Looking Statements In addition to historical information, this presentation may contain forward-looking statements with respect to our business, capital resources, strategy and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to a number of risks, unce ...

Company Overview - electroCore, Inc. is a bioelectronic medicine and wellness company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [4] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for chronic pain syndromes, and Quell Fibromyalgia [4] - electroCore also offers handheld products like Trvuaga and TAC-STIM nVNS for general wellness and human performance [4] Event Participation - Management will participate in the 38th Annual Roth Conference from March 22-24, 2026, at the Ritz-Carlton in Laguna Niguel, California [1] - Joshua Lev, the Chief Financial Officer, will host one-on-one meetings during the conference [1] - Investors interested in scheduling meetings can contact their Roth representative or email investors@electrocore.com for more information [2] Conference Details - The Annual Roth Conference is one of the largest in the nation for small-cap companies, featuring company presentations, Q&A sessions, and management one-on-one meetings [3] - Approximately 500 private and public companies from various growth sectors will be represented at the conference [3] - Roth's Research Team identifies distinguished presenting companies across sectors such as consumer, energy, healthcare, industrial growth, metals & mining, sustainability, services, and technology [3]

Core Insights - electroCore, Inc. will report its financial results for Q4 and the full year ended December 31, 2025, on March 19, 2026, after market close [1] - A webinar will be hosted by management at 4:30 PM EDT to review the financial results and address investor questions [2] Company Overview - electroCore, Inc. is a bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [3] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell® for fibromyalgia treatment [3] - Additionally, electroCore commercializes handheld products like Truvaga and TAC-STIM nVNS, aimed at promoting general wellness and human performance [3]

Core Insights - electroCore, Inc. will report its financial results for Q3 2025 on November 5, 2025, after market close [1] - A webinar will be held at 4:30 PM EST on the same day to discuss the results and answer investor questions [1] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [2] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [2] - Additionally, electroCore offers Truvaga and TAC-STIM products for general wellness and human performance enhancement [2]

Core Insights - electroCore, Inc. announced that its Truvaga™ Plus handheld vagus nerve stimulation device was named the "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards, highlighting its effectiveness in promoting relaxation and restorative sleep [1][2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies. Its leading products include gammaCore for chronic pain and Truvaga for general wellness [3][5] Product Details - Truvaga Plus is designed to activate the vagus nerve quickly and gently, promoting a balanced nervous system for improved calmness, clarity, and sleep. It is intended for general health and wellness and is not a medical device [5][6] - The device offers a drug-free alternative for relaxation and sleep, with sessions lasting just two minutes, making it convenient for daily use [8] Recognition and Validation - The recognition from Esquire serves as validation for Truvaga Plus, reinforcing consumer confidence in its effectiveness as a proven, non-drug solution for sleep and relaxation challenges [2][3]

Core Insights - electroCore, Inc. has appointed James C. Theofilos to its Board of Directors effective August 1, 2025, highlighting the company's commitment to enhancing its leadership team [1][2] - Mr. Theofilos brings nearly two decades of experience in finance and strategic growth, particularly in the healthcare and life sciences sectors, which is expected to benefit electroCore's operational discipline and innovation [2] - electroCore focuses on improving health and quality of life through non-invasive bioelectronic technologies, with its leading products including gammaCore and Quell neurostimulator for chronic pain treatment [3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company dedicated to innovative non-invasive solutions for health improvement [3] - The company's primary products, gammaCore and Quell, utilize non-invasive vagus nerve stimulation technology to address chronic pain syndromes [3] - Additionally, electroCore markets Truvaga products, which are designed for personal use to enhance general wellness and human performance [3]

Company Overview - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on multiple indications[6] - The company has FDA clearance for the prevention and treatment of primary headache in adults and adolescents[13] - The company has FDA authorization for symptoms of Fibromyalgia[13] Financial Performance and Projections - The company's revenue has a 5-year CAGR of 58%[7] - Revenue increased from $5.5 million in 2021 to $25.2 million in 2024[12] - Revenue is projected to reach $30 million in 2025[12] - Gross margins are approximately 85%[13] Market Opportunity - The total addressable market (TAM) for VA channel is $2.9 billion[15] - The total addressable market (TAM) for US commercial channel is $101 million[15] - The total addressable market (TAM) for Health & Wellness channel is $33 billion[15] - The total addressable market (TAM) for TAC-STIM is $9.7 billion[15] - $20 billion is spent annually out-of-pocket for chronic pain treatments[14]

Core Insights - electroCore, Inc. has been recognized by the Financial Times as one of "The Americas' Fastest Growing Companies 2025," debuting at number 125 among 300 companies [1][2] - The Financial Times' annual list ranks companies based on the highest compound annual revenue growth from 2020 to 2023, with the healthcare & life sciences sector representing 10% of the fastest-growing companies [2] - electroCore ranked 16th among 29 healthcare & life sciences companies included in the list, alongside notable firms such as BeiGene, Hims & Hers Health, and Progyny [2] Company Overview - electroCore is a commercial-stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform [4] - The company aims to commercialize medical devices for managing and treating specific medical conditions, as well as consumer products that utilize nVNS to enhance general well-being and human performance in the U.S. and select international markets [4] - The CFO of electroCore emphasized the company's commitment to delivering drug-free solutions for pain management, stress reduction, and sleep improvement, which contributed to its recognition by the Financial Times [3]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform [3] - The company aims to commercialize medical devices for managing and treating specific medical conditions, as well as consumer products that utilize nVNS to enhance general wellbeing and human performance in the United States and select international markets [3] Upcoming Event - Management will participate in the Needham Virtual Healthcare Conference on April 10, 2025, with a group presentation scheduled for 2:15 p.m. ET [1] - The presentation will be available via a live audio webcast, and a replay will also be accessible [2] - Investors interested in one-on-one meetings with management can arrange this through their Needham representative or by contacting the investor relations team [2]